As such, anti-IL-1β monoclonal antibodies (i.e., canakinumab) and IL-1β blockers (i.e., rilonacept) have been developed and show reduced cell proliferation, angiogenesis and metastasis of cancer cells in mice and in humans [65,66]. This evidence concerns the gene IL1B and cancer.